Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, especially in the field of vaccines. Recent volatility in the biotech stock market can be attributed to ongoing developments in the healthcare sector.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Jun 12, 2025 15:41

• Moderna (MRNA) saw a decline, potentially due to profit-taking following a period of strong performance.
• Positive outcomes from Novavax's COVID-flu combination shot trial may have diverted investor attention from Moderna temporarily.
• A legal win against Alnylam Pharmaceuticals in a patent dispute could have been overshadowed by broader market sentiment, impacting Moderna's stock negatively.
• Mirum Pharmaceuticals' financial results and subsequent stock movements could have influenced overall investor outlook on biotech stocks, including Moderna.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

https://www.zacks.com/stock/news/2495965/novavaxs-covid-flu-combo-shot-shows-strong-immune-response

Why Is Mirum Pharmaceuticals ( MIRM ) Down 1.3% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

https://www.zacks.com/stock/news/2487628/why-is-mirum-pharmaceuticals-mirm-down-13-since-last-earnings-report

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , Moderna ( NASDAQ:MRNA )

Appeals court affirmed that SM-102 does not infringe Alnylam's mRNA patents. The decision supports Moderna's use of SM-102 in its Spikevax COVID-19 vaccine. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre on Wednesday, June 11. The U.S.

https://www.benzinga.com/news/legal/25/06/45797712/moderna-beats-alnylam-appeal-in-covid-vaccine-patent-case

Trending Today

Jito ($JTO) Crypto Forecast: Up 17.6% Today

Solana ($SOL) Crypto Forecast: Up 6.8% Today

Moderna Inc. Price History

01.04.2025 - MRNA Stock was down 5.1%

• Moderna (MRNA) reported a Q1 loss and lagged revenue estimates, leading to a bearish movement in the stock.
• The market reacted negatively to the earnings surprises, with the stock settling at a -0.75% change from its previous close.
• Despite some bullish options trends, the overall sentiment towards Moderna seems to have been impacted by the earnings report.
• Investors are likely cautious about the company's performance in the face of revenue challenges and may be awaiting pipeline updates for a potential turnaround in sentiment.

01.04.2025 - MRNA Stock was down 5.2%

• Moderna's stock closed at $27.19, down -0.75% from the previous close.
• The company reported mixed Q1 results, with a loss in EPS but revenue exceeding expectations. However, the delay in FDA approval for its Flu/COVID-19 combo shot until 2026 could have dampened investor sentiment.
• Moderna's focus on cost-cutting initiatives, despite beating earnings estimates, might have raised concerns about the company's future growth prospects.
• The market reaction could also be influenced by uncertainties surrounding the company's sales guidance for 2025 and questions about its performance in the upcoming quarters.

21.03.2025 - MRNA Stock was up 5.1%

• Despite Moderna's stock dropping slightly at the closing of the latest trading day, the overall bullish movement could be attributed to positive market sentiment and investor confidence in the company's innovative mRNA technology.
• The US Advisory Panel's vote to expand recommendations for Pfizer, GSK's RSV vaccines for older adults below 60 years might have indirectly benefited Moderna as a fellow player in the pharmaceutical industry, leading to increased investor interest and a bullish market movement for MRNA.
• Investors may have interpreted the news as a sign of potential growth opportunities for Moderna in the vaccine market, contributing to the bullish movement in the stock price.

21.04.2025 - MRNA Stock was down 8.1%

• Despite the FDA's stricter standards for COVID-19 shots, MRNA and PFE stocks saw a jump. This could indicate that investors are still optimistic about the companies' abilities to navigate regulatory challenges.
• The options frenzy on Moderna showed a bearish trend, with a majority of traders exhibiting bearish tendencies. This could have contributed to the overall negative movement in MRNA stock today.
• The conflicting signals from different sources might have caused confusion among investors, leading to increased selling pressure on MRNA shares.

06.04.2025 - MRNA Stock was down 6.4%

• Moderna experienced a drop in its stock price as reactions were negative towards a decrease in COVID-19 vaccine demand and setbacks in FDA approval for a flu/COVID-19 combo shot.
• The company surpassed earnings per share expectations, but concerns remain due to a focus on cost reduction and product portfolio expansion that did not fully alleviate worries about revenue dips and vaccine approval delays.
• Market fluctuations were possibly due to investors reassessing Moderna's future growth potential post-pandemic, resulting in stock sales driven by uncertainties surrounding upcoming revenue sources.

12.05.2025 - MRNA Stock was down 5.1%

• Moderna (MRNA) saw a decline, potentially due to profit-taking following a period of strong performance.
• Positive outcomes from Novavax's COVID-flu combination shot trial may have diverted investor attention from Moderna temporarily.
• A legal win against Alnylam Pharmaceuticals in a patent dispute could have been overshadowed by broader market sentiment, impacting Moderna's stock negatively.
• Mirum Pharmaceuticals' financial results and subsequent stock movements could have influenced overall investor outlook on biotech stocks, including Moderna.

10.03.2025 - MRNA Stock was down 8.5%

• The recent rise in bearish options activity on Moderna suggests a lack of confidence or negative sentiment among investors, potentially leading to a stock sell-off.
• This bearish trend might be driven by profit-taking actions following a period of strong performance or concerns about the company's future growth.
• The approval of Vertex's Kaftrio for expanded use in Europe may have shifted investor focus and funds away from Moderna, influencing the bearish market movement.
• In general, the uptick in bearish options activity and positive developments for a competitor in the biotech industry likely impacted Moderna's bearish performance today.

06.05.2025 - MRNA Stock was up 5.3%

• Moderna (MRNA) witnessed a notable bullish movement in the market recently.
• This upward trend could be linked to a recent court ruling stating that SM-102, a crucial ingredient in Moderna's Spikevax COVID-19 vaccine, does not violate Alnylam Pharmaceuticals' mRNA patents. This legal victory likely boosted investor confidence in Moderna's vaccine technology and market position.
• Furthermore, reports of significant financial institutions taking bearish positions on Moderna may have presented a short-term buying opportunity for traders, resulting in increased demand for the stock and contributing to its bullish movement.
• Taken together, the positive legal outcomes and strategic trading activities are believed to have driven Moderna's stock price higher on the given day.

27.04.2025 - MRNA Stock was up 5.3%

• Moderna's bullish movement results from the company's seeking FDA approval for an updated COVID-19 vaccine targeting the LP.8.1 variant, prevalent in the U.S., showcasing its proactive response to new COVID-19 strains and market competitiveness.
• Despite an initial setback due to the withdrawal of the FDA filing for the COVID-Flu combo shot, the positive news about seeking approval for an updated COVID-19 vaccine overshadowed the issue, contributing to the stock's positive movement.
• Moderna's stock surged alongside Pfizer's and BioNTech's following the FDA's stricter standards for COVID-19 shots, reflecting investor confidence in these companies' capabilities to overcome regulatory hurdles and provide solutions for high-risk populations.

03.05.2025 - MRNA Stock was up 5.1%

• Moderna's stock surged after the company announced FDA clearance for its new COVID-19 vaccine, mNEXSPIKE, specifically tailored for seniors and at-risk individuals.
• The new vaccine demonstrated significantly higher efficacy compared to the company's original vaccine, showcasing a positive outlook for Moderna's vaccine portfolio.
• The cancellation of the government funding contract for Moderna's bird flu shot did not seem to deter investor confidence, as the focus remained on the promising developments in the COVID-19 vaccine sector.
• Overall, Moderna's bullish movement can be attributed to the positive news surrounding the efficacy and FDA clearance of its new COVID-19 vaccine, overshadowing the setbacks in other vaccine projects.

16.04.2025 - MRNA Stock was up 7.2%

• Moderna's stock surged significantly today, despite signs of bearish options activity.
• The divergence between short-term speculative views and long-term investor confidence in Moderna's growth potential may explain this stock movement.
• Positive updates on Moderna's vaccine progress or a positive market sentiment towards the biotech sector could have fueled this bullish momentum, overshadowing bearish options signals.

16.04.2025 - MRNA Stock was up 7.2%

• Despite the options frenzy and bearish moves by financial giants, Moderna's stock saw a strong bullish movement today.
• The unusual options trades and the majority of traders showing bearish tendencies did not align with the actual market performance of Moderna.
• This discrepancy could be attributed to unexpected positive news or developments regarding Moderna's vaccine technology or pipeline, leading to increased investor confidence and driving the stock price higher.
• It's essential for traders to consider all available information and not solely rely on options activity when making investment decisions, as market movements can sometimes defy conventional expectations.